JP2024546026A5 - - Google Patents
Info
- Publication number
- JP2024546026A5 JP2024546026A5 JP2024527503A JP2024527503A JP2024546026A5 JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5 JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024527503 A JP2024527503 A JP 2024527503A JP 2024546026 A5 JP2024546026 A5 JP 2024546026A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ala
- approximately
- ile
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111341752 | 2021-11-12 | ||
| CN202111341752.0 | 2021-11-12 | ||
| PCT/CN2022/131375 WO2023083301A1 (zh) | 2021-11-12 | 2022-11-11 | Glp-1受体和gip受体双重激动剂的药物组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546026A JP2024546026A (ja) | 2024-12-17 |
| JP2024546026A5 true JP2024546026A5 (https=) | 2025-11-11 |
Family
ID=86335124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527503A Pending JP2024546026A (ja) | 2021-11-12 | 2022-11-11 | Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250115654A1 (https=) |
| EP (1) | EP4431522A4 (https=) |
| JP (1) | JP2024546026A (https=) |
| KR (1) | KR20240109258A (https=) |
| CN (1) | CN118103391A (https=) |
| AU (1) | AU2022386489A1 (https=) |
| CA (1) | CA3237796A1 (https=) |
| MX (1) | MX2024005663A (https=) |
| TW (1) | TW202333773A (https=) |
| WO (1) | WO2023083301A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| TW202529797A (zh) * | 2023-12-12 | 2025-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途 |
| WO2025149039A1 (zh) * | 2024-01-12 | 2025-07-17 | 杭州中美华东制药有限公司 | 长效glp-1/gip双激动剂的药物组合物 |
| WO2025252197A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏恒瑞医药股份有限公司 | 药物组合物 |
| WO2026037397A1 (zh) * | 2024-08-16 | 2026-02-19 | 江苏恒瑞医药股份有限公司 | Glp-1类似物的医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101987868B (zh) * | 2009-07-30 | 2013-09-04 | 江苏豪森医药集团有限公司 | Glp-1类似物的衍生物或其可药用盐和用途 |
| WO2012088379A2 (en) * | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US9453062B2 (en) * | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| IN2014MN02304A (https=) * | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| AU2013366692B2 (en) * | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| EP3642238A1 (en) * | 2017-06-21 | 2020-04-29 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins |
| SG11202103137WA (en) * | 2018-10-26 | 2021-04-29 | Novo Nordisk As | Stable semaglutide compositions and uses thereof |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| US20220372072A1 (en) * | 2019-09-19 | 2022-11-24 | Dr. Reddy's Laboratories Limited | Improved purification processes for liraglutide |
| EP4086277A4 (en) * | 2019-12-30 | 2024-02-14 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting glp-1 compound |
| CN114222755B (zh) * | 2020-05-29 | 2024-06-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
-
2022
- 2022-11-11 US US18/709,004 patent/US20250115654A1/en active Pending
- 2022-11-11 EP EP22892094.8A patent/EP4431522A4/en active Pending
- 2022-11-11 TW TW111143259A patent/TW202333773A/zh unknown
- 2022-11-11 AU AU2022386489A patent/AU2022386489A1/en active Pending
- 2022-11-11 MX MX2024005663A patent/MX2024005663A/es unknown
- 2022-11-11 CN CN202280069025.XA patent/CN118103391A/zh active Pending
- 2022-11-11 JP JP2024527503A patent/JP2024546026A/ja active Pending
- 2022-11-11 KR KR1020247018683A patent/KR20240109258A/ko active Pending
- 2022-11-11 CA CA3237796A patent/CA3237796A1/en active Pending
- 2022-11-11 WO PCT/CN2022/131375 patent/WO2023083301A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024546026A5 (https=) | ||
| JP7461997B2 (ja) | 制御放出および持続的放出のためのｅｌｐ融合タンパク質 | |
| US7939494B2 (en) | Method for administering GLP-1 molecules | |
| US20090186819A1 (en) | Formulation of insulinotropic peptide conjugates | |
| WO2021136296A1 (zh) | 胰岛素衍生物 | |
| JP2006520818A (ja) | ポリエチレングリコール結合ｇｌｐ−１化合物 | |
| JP2023526973A5 (https=) | ||
| JP2006520818A5 (https=) | ||
| KR20210081389A (ko) | 글루카곤 유사 펩티드 1(glp1)-성장 분화 인자 15(gdf15) 융합 단백질 및 이의 용도 | |
| JP2011506442A5 (https=) | ||
| WO2011109787A1 (en) | Methods of administering insulinotropic peptides | |
| JP2024546026A (ja) | Ｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストの医薬組成物及びその使用 | |
| WO2023098777A1 (zh) | Glp-1和gip受体双重激动剂的药物组合物及其用途 | |
| WO2023143458A1 (zh) | 酰化胰岛素 | |
| CN119386161A (zh) | 用fgf21变体治疗代谢障碍的方法 | |
| US12551541B2 (en) | Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor | |
| EA053272B1 (ru) | Фармацевтическая композиция двойного агониста рецептора glp-1 и рецептора gip и ее применение | |
| HK1166449B (en) | Method for administering glp-1 molecules |